Mum 'reassured' over Batten disease drug access decision
"To know that he will have that treatment now for the rest of his life is incredible, it's so reassuring."Emily's four-year-old son, Max, from Spinkhill, near Killarmarsh in Derbyshire, has CLN2 Batten disease, a rare degenerative genetic disorder that causes a decline in a child's ability to walk, speak and see.He is symptom-free and has been receiving Brineura, the only approved treatment that slows the condition's progress, since he was one.NHS access to the drug, which costs over £500,000 per patient per year, had been due to expire at the end of May, however an agreement was reached allowing existing patients to continue to have it.
However, it has not been recommended for future patients diagnosed beyond the end of 2025 "due to its high price and the limited evidence of long-term effectiveness", said the National Institute for Health and Care Excellence (NICE).
Max goes to Manchester Children's Hospital every two weeks to receive treatment."He has to stay on the bed for four hours, but because he's had this treatment since he was a baby he doesn't really know any different so he likes it," Emily said."He says he's 'going to get his medicine' and sees the doctors."His dad, James, said Max receiving the treatment from a young age "has been absolutely key in the happy little boy that you see".He added: "He's progressing amazingly well in terms of his abilities."He's still symptom-free in terms of Batten disease, so it's a real success for the drug."
Max's older sister, Holly, also has Batten disease and had been receiving Brineura as part of her treatment.However, the six-year-old was diagnosed later in life and the family felt she was not getting as much benefit from the drug as her symptoms increased and agreed it should be stopped.James said: "Holly was on the treatment for around 12 months, but in that time her condition progressed and she started to lose more and more of her abilities."Within the space of a year, she'd gone from being a relatively normal and happy four-year-old to not being able to walk, losing all of her speech and losing her ability to eat and swallowing normally."
Emily and James's youngest child, four-month-old Rory, was born after the couple underwent in vitro fertilisation treatment.Embryos were screened in advance to check if the condition might be passed on again and, as a result, Rory does not have Batten disease.Emily said: "We were lucky to get four embryos that were unaffected and Rory was the first one that we transferred, so he's a healthy baby."On the decision to stop the use of Brineura for children not yet diagnosed with Batten disease, NICE said: "This committee took into account the condition's rarity, severity and the effect of cerliponase alfa [the drug marketed as Brineura] on quality and length of life."But using the proposed price of the medicine, the most likely-cost effectiveness estimate is not within what NICE considers an acceptable use of NHS resources."So, cerliponase alfa is not recommended."In response, the Batten Disease Family Association said: "Whilst this is naturally disappointing, it is important to note that this is not NICE's final guidance on the future of Brineura on the NHS."The NICE committee will meet again in July to consider evidence and consultation feedback in relation to whether patients not currently diagnosed with Batten disease could receive the drug in future.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sky News
40 minutes ago
- Sky News
One million blood donors needed to meet demand and avoid 'red alert' shortage, NHS warns
The NHS has warned the UK needs one million regular blood donors to maintain supply and avoid a "red alert" - which means supplies are so low there is a threat to public safety. Last July, officials issued an "amber alert" for stocks of O negative and O positive blood after cyberattacks hit London hospitals. NHS Blood and Transplant (NHSBT) said blood stocks have remained low since. Dr Jo Farrar, NHSBT chief executive, said: "Our stocks over the past 12 months have been challenging. If we had a million regular donors, this would help keep our stocks healthy - you'd truly be one in a million. "Please book an appointment today, experience how good it feels to save lives, and come and do it again in a few months." The NHSBT added just 2% of the population - under 800,000 people - sustained the whole of England's blood supply over the past 12 months. It said there is a "critical" need for more donors who have O negative blood, the universal type used in emergencies or when a patient's blood type is unknown. It is typically carried by air ambulances and emergency vehicles - and makes up around 16% of hospital blood orders. There is also a need for more black donors, who are more likely to have specific blood types which can help treat people with sickle cell disease. Health Minister Baroness Merron said: "The NHS is in urgent need of more lifesaving blood donors from all backgrounds. "We are working alongside NHS Blood and Transplant to make donating blood easier than ever before, opening up new donor centres and making appointments available closer to home." Women can donate blood once every four months and men can do so once every three.
Glasgow Times
an hour ago
- Glasgow Times
Nurses to vote on pay deal amid concerns of industrial action
Around 345,000 members of the Royal College of Nursing (RCN) will be asked if the pay award is enough in what was described as the biggest single vote of the profession ever launched in the UK. Last month, the Westminster government accepted the recommendation of the Pay Review Body, giving nursing staff In England's NHS a pay rise of 3.6%. Royal College of Nursing general secretary Professor Nicola Ranger (RCN/PA) The RCN described the award as 'grotesque', saying it will see nursing staff receive a pay rise 'entirely swallowed up by inflation' – with doctors, teachers, prison officers and the armed forces all receiving a bigger increase. An identical award was made in Wales, while in Northern Ireland, the Health Minister has announced his wish to implement a 3.6% pay rise, but this is still to be agreed. The RCN said the vote will be crucial in determining the next steps, which could include a ballot for strike action. The vote will include RCN members working in the NHS in England, Wales and Northern Ireland. Speaking from an international nursing conference in Helsinki and on the launch of the vote, Professor Nicola Ranger, RCN general secretary, will say: 'I'm with nurses from around the world today asking why it is our ministers in the UK who have once again put nursing at the back of the queue when it comes to pay. 'Nursing is an incredible career, but despite being the most valued profession by the public we continue to be weighted to the bottom of the NHS pay scale and are set to receive one of the lowest pay awards. 'It is time to show that nurses are valued and, from today, hundreds of thousands of nursing staff working in the NHS will give their verdict on whether 3.6% is enough.' The RCN said nursing staff in England have faced more than a decade of pay erosion since 2010/11, with pay down by a quarter in real terms. As a result, there are more than 26,000 unfilled nursing posts, while student recruitment has 'collapsed' and the numbers quitting is 'skyrocketing', said the RCN. Professor Ranger will add: 'Over a decade of pay erosion has had a devastating impact on our profession, forcing increasing numbers into quitting while putting off the nurses of the future. 'When our members vote, they won't just be voting on the fairness of the award for themselves, but if it's enough to turn our profession around.' NHS workers including nurses staged a series of strikes under the previous Conservative government in bitter disputes over pay.
Telegraph
an hour ago
- Telegraph
World must ‘start screening for prostate cancer to stop men being left behind'
Every country should have a strategy for tackling prostate cancer with dedicated screening programs for men over 50, a leading health charity has said. Global Action on Men's Health, the leading international charity for men's health, is calling for prostate cancer – now the third most common cancer worldwide – to be dramatically elevated on the health agenda. On Monday it will launch a campaign to encourage all countries with adequate resources, including the UK, to launch national screening for the disease in a bid to cut unnecessary deaths. It will also call for the World Health Organization (WHO) to introduce a Global Prostate Cancer Initiative which 'covers every stage of the prostate cancer pathway from prevention to palliative care'. Prostate cancer is now the most frequently diagnosed cancer in men in 112 countries and the leading cause of cancer death among men in 48 countries. In England, it is now the most common cancer, killing some 12,000 men every year, according to Prostate Cancer UK. Writing in today's Telegraph, Peter Baker, the director of Global Action on Men's Health, said that men were being short-changed when it comes to healthcare. 'Men's health has been neglected for far too long with devastating consequences,' he writes. 'Globally, men's life expectancy lags five years behind women's. Men are significantly more likely to develop and die from cancer, heart disease, diabetes and tuberculosis. They are also at much greater risk of dying from suicide or an accident on the roads or at work.' Mr Baker calls for reform across health care systems – ensuring men have better access to GPs, for instance – and believes that a focus on prostate cancer is a good place to start. Rapid advances in screening technologies now mean that developed nations should soon be able to launch screening programs that will cut death rates by a third or more and reduce the dramatic social inequalities associated with the disease. Men with a family history of prostate cancer run a significantly higher genetic risk of developing prostate cancer, as do black men. Men from lower socioeconomic backgrounds are also much harder hit, due to a combination of poor health literacy and access to healthcare. The European Commission recently recommended introducing national prostate cancer screening across all 27 member states of the European Union, and already countries including Sweden and Norway have either launched or are on the brink of launching national screening programs. While blood tests for prostate cancer, known as prostate-specific antigen tests (PSA), have been available for many years, they throw up a large number of false positives. This in turn led to many unnecessary prostate removals and biopsies being performed, meaning the risks outweighed the benefits of running national screening programmes. But now, with the advent of more specific blood tests and high resolution MRI scans, which allow for much more accurate biopsies, the balance has changed, with several high quality studies showing the benefit of screening. The largest of these studies was the European Randomised Study of Screening for Prostate Cancer (ERSPC), which included over 182,000 men and showed a 20 per cent reduction in prostate cancer mortality among those screened. Another study in Gothenburg, Sweden, found that after 18 years of follow-up, men in the screening group were 35 per cent less likely to die from prostate cancer than men who were not screened. Men who started screening at age 55-59 were 53 per cent less likely to die. Professor Jonas Hugosson, a urologist at University of Gothenburg in Sweden who led the Swedish study, said he expected national screening for prostate cancer to be rolled out across most western European nations in the next few years. In Sweden a move to nationwide screening was already progressing and in Norway he expected a national screening program to be announced shortly, he said. However, just as with the roll out of breast cancer screening more than three decades ago, it would take most countries many years to gear up. 'In my view, we have quite a new situation today, and I think it's time for the health authorities to take a new standpoint,' he said. 'I'm quite sure about that and we will see screening come all over Europe during the coming years, but it takes 10 years to build up, at least.' 'Alarming and unacceptable' rise in cases The NHS in England does not have a dedicated men's health strategy but one has been promised by the end of the year by the new Health Secretary, Wes Streeting. Although the new strategy is unlikely to include the imminent launch of a national screening program for prostate cancer – the UK currently does not have the MRI machines and trained staff needed to launch one – it may include screening for high risk groups. These include black men, who have double the normal risk, and men with a family history of prostate and related cancers – including breast and ovarian cancer on the female side. In October last year, six-time Olympic cycling champion Sir Chris Hoy, 49, revealed that he had terminal prostate cancer. Both his father and grandfather had the disease but his was not caught by early testing, sparking an outcry. 'The rapid rise in prostate cancer cases is not just alarming, it is also unnecessary and therefore unacceptable,' said Global Action on Men's Health. 'Prostate cancer is currently inadequately addressed in global and national cancer policies'. In addition to national testing where possible, the charity is calling for the WHO to support a new Global Prostate Cancer Initiative covering 10 areas. These include governments being urged to introduce national cancer plans which specifically address prostate cancer with clear performance indicators, education programmes to raise awareness and tackle stigma, and investments in research, infrastructure, workforce development and treatments for prostate cancer. The WHO does not currently have a programme that focuses specifically on prostate cancer but 'integrates' it to its wider program for tackling cancer more generally. Cervical cancer, in contrast, has a dedicated programme dedicated to its global eradication but that is because the HPV vaccine makes it possible to wipe out the disease completely. Dr André Ilbawi, technical lead for cancer control at the WHO, welcomed the prostate campaign launched by Global Action on Men's Health, and said the disease was moving up the WHO's agenda. The organisation had just five countries involved in its cancer programme in 2015 to but has 100 today. 'We see prostate cancer as a priority and, in 2023, elevated it in our guidance because it can be treated,' said Dr IIbawi. 'If treatment is available, survival is extremely high. And if treatments are not available, those men will die. 'We agree that prostate cancer should be seen in the cancer agenda as high impact, cost-effective and meeting community needs'.
